- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 15, Issue 4, Pages 234-248
Publisher
Springer Nature
Online
2018-02-06
DOI
10.1038/nrclinonc.2018.8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Do STAT3 inhibitors have potential in the future for cancer therapy?
- (2017) Andrea L.A. Wong et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer
- (2017) Marcela Moisés Maluf Sanguinete et al. IMMUNOLOGICAL INVESTIGATIONS
- STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC
- (2017) L.L. Bu et al. JOURNAL OF DENTAL RESEARCH
- Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity
- (2017) Ryota Tanaka et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
- (2017) Francesco Passamonti et al. LANCET ONCOLOGY
- PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
- (2017) V Atsaves et al. LEUKEMIA
- MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlates with poor prognosis
- (2017) Yan Yang et al. Molecular Cancer
- Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation
- (2017) Yubin Lei et al. Molecular Cancer
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe cytokine release syndrome in a patient receiving PD-1-directed therapy
- (2017) Seth J. Rotz et al. PEDIATRIC BLOOD & CANCER
- JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
- (2017) Chunwan Lu et al. OncoImmunology
- Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia
- (2016) Q. Zhang et al. BLOOD
- Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases
- (2016) M Thorn et al. CANCER GENE THERAPY
- IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis
- (2016) G. D. Brooks et al. CANCER RESEARCH
- A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors
- (2016) Haihong Zhong et al. CANCER RESEARCH
- Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity
- (2016) Seiichi Odate et al. CLINICAL CANCER RESEARCH
- The biology behind interleukin-6 targeted interventions
- (2016) Xiao Liu et al. CURRENT OPINION IN RHEUMATOLOGY
- IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
- (2016) Thomas A Mace et al. GUT
- The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
- (2016) Nan Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report
- (2016) Marc Uemura et al. Journal of Hematology & Oncology
- Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
- (2016) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma
- (2016) JIAN GAO et al. ONCOLOGY REPORTS
- The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations
- (2016) Jessica L. Geiger et al. ORAL ONCOLOGY
- Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells
- (2016) Haiyan S. Li et al. Science Signaling
- Role of interleukin-6 in cancer progression and therapeutic resistance
- (2016) Neeraj Kumari et al. TUMOR BIOLOGY
- Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial
- (2016) J J Shah et al. Blood Cancer Journal
- Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma
- (2016) Uddalak Bharadwaj et al. Oncotarget
- Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer
- (2016) Pradeep Chaluvally-Raghavan et al. Cell Reports
- Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells
- (2016) Haiyan S. Li et al. Science Signaling
- IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence
- (2016) Kelsey A. Finkel et al. NEOPLASIA
- Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic
- (2016) Mehrad Tavallai et al. Frontiers in Oncology
- A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer
- (2015) E. M. Dijkgraaf et al. ANNALS OF ONCOLOGY
- Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
- (2015) A. L. Wong et al. ANNALS OF ONCOLOGY
- Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
- (2015) R. S. Komrokji et al. BLOOD
- Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
- (2015) Michinori Ogura et al. CANCER SCIENCE
- The Opposing Function of STAT3 as an Oncoprotein and Tumor Suppressor Is Dictated by the Expression Status of STAT3 in Esophageal Squamous Cell Carcinoma
- (2015) H.-F. Zhang et al. CLINICAL CANCER RESEARCH
- Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma
- (2015) Takuji Okusaka et al. HEPATOLOGY RESEARCH
- Signal Transducer and Activator of Transcription 4 in Liver Diseases
- (2015) Yan Wang et al. International Journal of Biological Sciences
- Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer
- (2015) Freya A. Goumas et al. INTERNATIONAL JOURNAL OF CANCER
- Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma
- (2015) Kenshi Suzuki et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
- (2015) Herbert I. Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia
- (2015) E Andersson et al. LEUKEMIA
- Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary
- (2015) Nozomu Yanaihara et al. MOLECULAR CARCINOGENESIS
- Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)
- (2015) Lara Brambilla et al. Molecular Oncology
- IL-6 as a keystone cytokine in health and disease
- (2015) Christopher A Hunter et al. NATURE IMMUNOLOGY
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer
- (2015) N D Peyser et al. ONCOGENE
- Targeting JAK kinase in solid tumors: emerging opportunities and challenges
- (2015) M Buchert et al. ONCOGENE
- Emerging strategies for cancer immunoprevention
- (2015) J C Roeser et al. ONCOGENE
- Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma
- (2015) TEPPEI JINNO et al. ONCOLOGY REPORTS
- Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels
- (2015) Tomofumi Miura et al. PANCREAS
- A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
- (2015) Mignon L. Loh et al. PEDIATRIC BLOOD & CANCER
- Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer
- (2015) Noah D. Peyser et al. PLoS One
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
- (2015) David Hong et al. Science Translational Medicine
- Routine clinical markers of the magnitude of the systemic inflammatory response after elective operation: A systematic review
- (2015) David G. Watt et al. SURGERY
- The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease
- (2015) Beata Kotowicz et al. TUMOR BIOLOGY
- Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis
- (2015) Beatrice Grabner et al. Nature Communications
- Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells
- (2015) Can Küçük et al. Nature Communications
- Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
- (2015) Do-Youn Oh et al. Cancer Research and Treatment
- JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth
- (2015) Malabika Sen et al. NEOPLASIA
- Preclinical Evaluation of the Toxicological Effects of a Novel Constrained Ethyl Modified Antisense Compound Targeting Signal Transducer and Activator of Transcription 3 in Mice and Cynomolgus Monkeys
- (2015) Sebastien A. Burel et al. Nucleic Acid Therapeutics
- The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis
- (2015) Qing Chang et al. NEOPLASIA
- A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
- (2014) Robert Z. Orlowski et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
- (2014) J. San-Miguel et al. BLOOD
- Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance
- (2014) D. Gotthardt et al. BLOOD
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
- (2014) Ho-June Lee et al. CANCER CELL
- Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
- (2014) Johanna C. Bendell et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2014) E. Angevin et al. CLINICAL CANCER RESEARCH
- Interleukin-6 and its receptors: A highly regulated and dynamic system
- (2014) Janina Wolf et al. CYTOKINE
- A microRNA 221– and 222–Mediated Feedback Loop Maintains Constitutive Activation of NFκB and STAT3 in Colorectal Cancer Cells
- (2014) Sanhong Liu et al. GASTROENTEROLOGY
- IL-22+CD4+ T Cells Promote Colorectal Cancer Stemness via STAT3 Transcription Factor Activation and Induction of the Methyltransferase DOT1L
- (2014) Ilona Kryczek et al. IMMUNITY
- Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells
- (2014) YOUNG-AH SUH et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
- (2014) Matjaz Rokavec et al. JOURNAL OF CLINICAL INVESTIGATION
- STAT3, STAT4, NFATc1, and CTCF Regulate PD-1 through Multiple Novel Regulatory Regions in Murine T Cells
- (2014) J. W. Austin et al. JOURNAL OF IMMUNOLOGY
- Trans-Signaling Is a Dominant Mechanism for the Pathogenic Actions of Interleukin-6 in the Brain
- (2014) I. L. Campbell et al. JOURNAL OF NEUROSCIENCE
- Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer
- (2014) Lanxi Song et al. Journal of Thoracic Oncology
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
- (2014) Frits van Rhee et al. LANCET ONCOLOGY
- Unknown
- (2014) Malabika Sen et al. MOLECULAR MEDICINE
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer
- (2014) V. W. Y. Lui et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy
- (2014) Melanie Spitzner et al. Cancers
- Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity
- (2013) D. M. S. Hossain et al. BLOOD
- The role of intratumoral and systemic IL-6 in breast cancer
- (2013) Christine Dethlefsen et al. BREAST CANCER RESEARCH AND TREATMENT
- Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma
- (2013) C Gordziel et al. BRITISH JOURNAL OF CANCER
- MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis
- (2013) W Wu et al. BRITISH JOURNAL OF CANCER
- Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour–stroma interaction
- (2013) T Nagasaki et al. BRITISH JOURNAL OF CANCER
- The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
- (2013) Srdan Verstovsek et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
- (2013) Peter M. Voorhees et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells
- (2013) Eunhee Kim et al. CANCER CELL
- OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells
- (2013) Mi-Jung Kim et al. CANCER LETTERS
- A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation
- (2013) X. Zhang et al. CANCER RESEARCH
- miR-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma
- (2013) Jun Wei et al. CANCER RESEARCH
- The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo
- (2013) J.-H. Lee et al. CLINICAL CANCER RESEARCH
- A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
- (2013) R. Kurzrock et al. CLINICAL CANCER RESEARCH
- Fragment-based drug design and identification of HJC0123 , a novel orally bioavailable STAT3 inhibitor for cancer therapy
- (2013) Haijun Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
- (2013) Z. Kan et al. GENOME RESEARCH
- Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo
- (2013) XIAOLEI ZHANG et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Minimal Interleukin 6 (IL-6) Receptor Stalk Composition for IL-6 Receptor Shedding and IL-6 Classic Signaling
- (2013) Paul Baran et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- STAT3, a Poor Survival Predicator, Is Associated with Lymph Node Metastasis from Breast Cancer
- (2013) Yujuan Chen et al. Journal of Breast Cancer
- The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications—a review
- (2013) Antonio Macciò et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention
- (2013) K A Dorritie et al. LEUKEMIA
- IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus
- (2013) Miao-Fen Chen et al. Molecular Cancer
- AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors
- (2013) E. R. Plimack et al. ONCOLOGIST
- Stat3 Inhibitor Stattic Exhibits Potent Antitumor Activity and Induces Chemo- and Radio-Sensitivity in Nasopharyngeal Carcinoma
- (2013) Yunbao Pan et al. PLoS One
- Activation of STAT3 in Human Gastric Cancer Cells via Interleukin (IL)-6-Type Cytokine Signaling Correlates with Clinical Implications
- (2013) Zhengguang Wang et al. PLoS One
- Icaritin Inhibits JAK/STAT3 Signaling and Growth of Renal Cell Carcinoma
- (2013) Shasha Li et al. PLoS One
- The role of IL-6 in the radiation response of prostate cancer
- (2013) Chun-Te Wu et al. Radiation Oncology
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases
- (2013) F Hayakawa et al. Blood Cancer Journal
- Stat3 Activation in Urothelial Stem Cells Leads to Direct Progression to Invasive Bladder Cancer
- (2012) P. L. Ho et al. CANCER RESEARCH
- Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis
- (2012) Amir Sonnenblick et al. Clinical & Translational Oncology
- Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer
- (2012) M. Sen et al. CLINICAL CANCER RESEARCH
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
- (2012) Stefan Rose-John International Journal of Biological Sciences
- Phosphorylation of signal transducer and activator of transcription 3 in soft tissue leiomyosarcoma is associated with a better prognosis
- (2012) Nokitaka Setsu et al. INTERNATIONAL JOURNAL OF CANCER
- Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy
- (2012) Chin Hao Chang et al. INTERNATIONAL JOURNAL OF CANCER
- SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia
- (2012) Hanna L.M. Koskela et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
- (2012) X. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
- (2012) Malabika Sen et al. Cancer Discovery
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- The pro- and anti-inflammatory properties of the cytokine interleukin-6
- (2011) Jürgen Scheller et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
- (2011) Sally A. Hunsucker et al. BRITISH JOURNAL OF HAEMATOLOGY
- Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression
- (2011) Akihisa Fukuda et al. CANCER CELL
- Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
- (2011) Marina Lesina et al. CANCER CELL
- Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480
- (2011) H. Xin et al. CANCER RESEARCH
- Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
- (2011) Jermaine Coward et al. CLINICAL CANCER RESEARCH
- Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
- (2011) K. Fizazi et al. EUROPEAN JOURNAL OF CANCER
- A Critical Role for STAT3 Transcription Factor Signaling in the Development and Maintenance of Human T Cell Memory
- (2011) Andrea M. Siegel et al. IMMUNITY
- Enhanced Cancer Immunotherapy Using STAT3-Depleted Dendritic Cells with High Th1-Inducing Ability and Resistance to Cancer Cell-Derived Inhibitory Factors
- (2011) T. Iwata-Kajihara et al. JOURNAL OF IMMUNOLOGY
- Both miR-17-5p and miR-20a Alleviate Suppressive Potential of Myeloid-Derived Suppressor Cells by Modulating STAT3 Expression
- (2011) M. Zhang et al. JOURNAL OF IMMUNOLOGY
- Potent and Selective Phosphopeptide Mimetic Prodrugs Targeted to the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3
- (2011) Pijus K. Mandal et al. JOURNAL OF MEDICINAL CHEMISTRY
- Interleukin-6: A multifunctional targetable cytokine in human prostate cancer
- (2011) Zoran Culig et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- IL-6 Promotes Head and Neck Tumor Metastasis by Inducing Epithelial-Mesenchymal Transition via the JAK-STAT3-SNAIL Signaling Pathway
- (2011) A. Yadav et al. MOLECULAR CANCER RESEARCH
- NF-κB and STAT3 cooperatively induce IL6 in starved cancer cells
- (2011) S Yoon et al. ONCOGENE
- Dynamics of the STAT3 Transcription Factor: Nuclear Import Dependent on Ran and Importin-β1
- (2011) Velasco Cimica et al. PLoS One
- The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study
- (2011) Jayaprakash Karkera et al. PROSTATE
- A novel small-molecule disrupts Stat3 SH2 domain–phosphotyrosine interactions and Stat3-dependent tumor processes
- (2010) Xiaolei Zhang et al. BIOCHEMICAL PHARMACOLOGY
- A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
- (2010) J-F Rossi et al. BRITISH JOURNAL OF CANCER
- Targeting Stat3 in the Myeloid Compartment Drastically Improves the In vivo Antitumor Functions of Adoptively Transferred T Cells
- (2010) A. Herrmann et al. CANCER RESEARCH
- Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects
- (2010) M. Kujawski et al. CANCER RESEARCH
- Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
- (2010) T. B. Dorff et al. CLINICAL CANCER RESEARCH
- Prognostic significance of nuclear pSTAT3 in oral cancer
- (2010) Muzafar A. Macha et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines
- (2010) Wiltrud Lederle et al. INTERNATIONAL JOURNAL OF CANCER
- Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease
- (2010) Frits van Rhee et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
- (2010) Debra M Meyer et al. Journal of Inflammation-London
- STAT3 Activation of miR-21 and miR-181b-1 via PTEN and CYLD Are Part of the Epigenetic Switch Linking Inflammation to Cancer
- (2010) Dimitrios Iliopoulos et al. MOLECULAR CELL
- Protein Tyrosine Phosphatases, TC-PTP, SHP1, and SHP2, Cooperate in Rapid Dephosphorylation of Stat3 in Keratinocytes Following UVB Irradiation
- (2010) Dae Joon Kim et al. PLoS One
- Identification of a New Series of STAT3 Inhibitors by Virtual Screening
- (2010) Kenji Matsuno et al. ACS Medicinal Chemistry Letters
- Rapid and sustained improvement in bone and cartilage turnover markers with the antiâinterleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone
- (2009) Patrick Garnero et al. ARTHRITIS AND RHEUMATISM
- LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model
- (2009) B Fuh et al. BRITISH JOURNAL OF CANCER
- Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma
- (2009) S Takemoto et al. BRITISH JOURNAL OF CANCER
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
- (2009) Michael Hedvat et al. CANCER CELL
- IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer
- (2009) Sergei Grivennikov et al. CANCER CELL
- Stat3 Is a Negative Regulator of Intestinal Tumor Progression in ApcMin Mice
- (2009) Monica Musteanu et al. GASTROENTEROLOGY
- Serum interleukin-6 levels in colorectal cancer patients—a summary of published results
- (2009) Heike Knüpfer et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Targeting Signal Transducer and Activator of Transcription Signaling Pathway in Leukemias
- (2009) Mustafa Benekli et al. JOURNAL OF CLINICAL ONCOLOGY
- Essential Roles of IL-6 Trans-Signaling in Colonic Epithelial Cells, Induced by the IL-6/Soluble-IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated Premalignant Cancer in a Murine Model
- (2009) S. Matsumoto et al. JOURNAL OF IMMUNOLOGY
- The Role of STAT-3 in the Induction of Apoptosis in Pancreatic Cancer Cells by Benzyl Isothiocyanate
- (2009) R. P. Sahu et al. JNCI-Journal of the National Cancer Institute
- Constitutive activation and targeted disruption of signal transducer and activator of transcription 3 (Stat3) in mouse epidermis reveal its critical role in UVB-induced skin carcinogenesis
- (2009) D J Kim et al. ONCOGENE
- Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells
- (2009) N J Sullivan et al. ONCOGENE
- Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells
- (2009) M Walter et al. ONCOGENE
- Stat3 Promotes Metastatic Progression of Prostate Cancer
- (2008) Junaid Abdulghani et al. AMERICAN JOURNAL OF PATHOLOGY
- Interleukin-6 predicts recurrence and survival among head and neck cancer patients
- (2008) Sonia A. Duffy et al. CANCER
- Role of Stat3 in suppressing anti-tumor immunity
- (2008) Marcin Kortylewski et al. CURRENT OPINION IN IMMUNOLOGY
- Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice
- (2008) Maciej Kujawski et al. JOURNAL OF CLINICAL INVESTIGATION
- Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT)
- (2008) Yukiyasu Ozawa et al. LEUKEMIA RESEARCH
- Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival
- (2008) Chun-Liang Chen et al. Molecular Cancer
- Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours
- (2008) Sandra Rebouissou et al. NATURE
- Interleukin-6 and cachexia in ApcMin/+ mice
- (2007) Kristen A. Baltgalvis et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now